Heregulin-induced apoptosis

Apoptosis

Volumn 7, Issue 6, 2002, Pages 483-491

  Le, X F ^a   Varela, C R ^a   Bast Jr , R C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; Bcl 2; Breast cancer; Caspase 7; HER2; Heregulin

Indexed keywords

CASPASE 7; CASPASE 9; HEREGULIN 2; ISOPROTEIN; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; NEU DIFFERENTIATION FACTOR; PROTEIN; PROTEIN BCL 2; PROTEIN KINASE C ALPHA; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; CASP7 PROTEIN, HUMAN; CASP9 PROTEIN, HUMAN; CASPASE; MITOGEN ACTIVATED PROTEIN KINASE; PRKCA PROTEIN, HUMAN; PROTEIN KINASE; PROTEIN KINASE C;

ALTERNATIVE RNA SPLICING; APOPTOSIS; BREAST CANCER; CELL CYCLE G2 PHASE; CELL DIFFERENTIATION; ENZYME ACTIVATION; GROWTH INHIBITION; GROWTH STIMULATION; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SHORT SURVEY; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; CELL DIVISION; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

JANUS;

ALTERNATIVE SPLICING; ANIMALS; APOPTOSIS; CASPASE 7; CASPASE 9; CASPASES; CELL DIVISION; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, BIOLOGICAL; NEUREGULIN-1; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 0036889246     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020682807922     Document Type: Short Survey

References (67)

1. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997; 410: 83-86.
2. Riese DJ 2nd, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998; 20: 41-48.
3. Adlkofer K, Lai C. Role of neuregulin in glial cell development. Glia 2000; 29: 104-111.
4. Holmes WE, Sliwkowski MX, Akita RW, et al. Identification of heregulin: A specific activator of p185erbB2. Science 1992; 256: 1205-1210.
5. Wen D, Peles E, Cuppies R, et al. Neu differentiation factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 1992; 69: 559-572.
6. Peles E, Bacus SS, Koski RA, et al. Isolation of the neu/HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 1992; 69: 205-216.
7. Culouscou JM, Plowman GD, Carlton GW, et al. Characterization of a breast cancer cell differentiation factor that specifically activates the HER4/p180erbB4 receptor. J Biol Chem 1993; 268: 18407-18410.
8. Carraway KL 3rd, Weber JL, Unger MJ, et al. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature 1997; 387: 512-516.
9. Chang H, Riese DJ 2nd, Gilbert W, et al. Ligands for ErbB-family receptors encoded by a neuregulin-like gene. Nature 1997; 387: 509-512.
10. Zhang D, Sliwkowski MX, Mark M, et al. Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates ErbB4. Proc Natl Acad Sci USA 1997; 94: 9562-9567.
11. Harari D, Tzahar E, Romano J, et al. Neuregulin-4: A novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene 1999; 18: 2681-2689.
12. Orr-Urtreger A, Trakhtenbrot L, Ben-Levy R, et al. Neural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21. Proc Natl Acad Sci USA 1993; 90: 1867-1871.
13. Ring HZ, Chang H, Guilbot A, et al. The human neuregulin-2 gene: Cloning, mapping and evaluation as a candidate for the autosomal recessive form of Charcot-Marie-Tooth disease linked to 5q. Hum Genet 1999; 104: 326-332.
14. Gizatullin RZ, Muravenko OV, Al-Amin AN, et al. Human NRG3 gene map position 10q22-q23. Chromosome Res 2000; 8: 560.
15. Pinkas-Kramarski R, Shelly M, Guarino BC, et al. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol 1998; 18: 6090-6101.
16. Jones JT, Akita RW, Sliwkowski MX. Binding specificity and affinity of EGF domains for ErbB receptors. FEBS Lett 1999; 447: 227-231.
17. HER2 with a monoclonal antibody and with heregulin β1 in SKBr3 cells. Cancer Res 2000; 60: 3522-3531.
18. Barnes CJ, Li F, Mandal M, Yang Z, et al. Heregulin induces expression, ATPase activity, and nuclear localization of G3BP, a Ras signaling component, in human breast tumors. Cancer Res 2002; 62: 1251-1255.
19. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature 1995; 378: 386-390.
20. Gassmann M, Casagranda F, Orioli D, et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 1995; 378: 390-394.
21. Lee KF, Simon H, Chen H, et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995; 378: 394-398.
22. Lewis GD, Lofgren JA, McMurtrey AE, et al. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res 1996; 56: 1457-1465.
23. Beerli RR, Hynes NE. Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J Biol Chem 1996; 271: 6071-6076.
24. Aguilar Z, Akita RW, Finn RS, et al. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene 1999; 18: 6050-6062.
25. Weinstein EJ, Leder P. The extracellular region of heregulin is sufficient to promote mammary gland proliferation and tumorigenesis but not apoptosis. Cancer Res 2000; 60: 3856-3861.
26. Krane IM, Leder P. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene 1996; 12: 1781-1788.
27. Bagheri-Yarmand R, Vadlamudi RK, Wang RA, et al. Vascular endothelial growth factor upregulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis. J Biol Chem 2000; 275: 39451-39457.
28. Yen L, You XL, Al Moustafa AE, et al. Heregulin selectively up-regulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000; 19: 3460-3469.
29. Xu FJ, Stack S, Boyer C, et al. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): Increased invasiveness may contribute to poor prognosis. Clin Cancer Res 1997; 3: 1629-1634.
30. Tan M, Grijalva R, Yu D. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase. Cancer Res 1999; 59: 1620-1625.
31. Hijazi MM, Thompson EW, Tang C, et al. Heregulin regulates the acrin cytoskeleton and promotes invasive properties in breast cancer cell lines. Int J Oncol 2000; 17: 629-641.
32. Bacus SS, Huberman E, Chin D, et al. A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells. Cell Growth Differ 1992; 3: 401-411.
33. Daly JM, Jannot CB, Beerli RR, et al. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. Cancer Res 1997; 57: 3804-3811.
34. Le XF, McWatters A, Wiener J, et al. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res 2000; 6: 260-270.
35. Jones FE, Jerry DJ, Guarino BC, et al. Heregulin induces in vivo proliferation and differentiation of mammary epithelium into secretory lobuloalveoli. Cell Growth Differ 1996; 7: 1031-1038.
36. Grimm S, Leder P. An apoptosis-inducing isoform of neu differentiation factor (NDF) identified using a novel screen for dominant, apoptosis-inducing genes. J Exp Med 1997; 185: 1137-1142.
37. Grimm S, Weinstein EJ, Krane IM, Leder P. Neu differentiation factor (NDF): A dominant oncogene, causes apoptosis in vitro and in vivo. J Exp Med 1998; 188: 1535-1539.
38. Weinstein EJ, Grimm S, Leder P. The oncogene heregulin induces apoptosis in breast epithelial cells and tumors. Oncogene 1998; 17: 2107-2113.
39. Daly JM, Olayioye MA, Wong AM, et al. NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: Role of P13 kinase and p38 MAP kinase pathways. Oncogene 1999; 18: 3440-3451.
40. Guerra-Vladusic FK, Scott G, Weaver V, et al. Constitutive expression of Heregulin induces apoptosis in an erbB-2 over-expressing breast cancer cell line SKBr-3. Int J Oncol 1999; 15: 883-892.
41. Le XF, Marcelli M, McWarrers A, et al. Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity. Oncogene 2001; 20: 8258-8269.
42. Xu FJ, Yu YH, Le XF, et al. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res 1999; 5: 3653-3660.
43. Giani C, Casalini P, Pupa SM, et al. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation. Oncogene 1998; 17: 425-432.
44. Sepp-Lorenzino L, Eberhard I, Ma Z, et al. Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells. Oncogene 1996; 12: 1679-1687.
45. Sartor CI, Zhou H, Kozlowska E, et al. HER4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 2001; 21: 4265-4275.
46. Guerra-Vladusic FK, Vladusic EA, Tsai MS, Lupu R. Signaling molecules implicated in heregulin induction of growth arrest and apoptosis. Oncol Rep 2001; 8: 1203-1214.
47. Rouse J, Cohen P, Trigon S, et al. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 1994; 78: 1027-1037.
48. Hagemann C, Blank JL. The ups and downs of MEK kinase interactions. Cell Signal 2001; 13: 863-875.
49. Caron E, Hall A. Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases. Science 1998; 282: 1717-1721.
50. Hauck CR, Meyer TF, Lang F, Gulbins E. CD66-mediated phagocytosis of Opa52 Neisseria gonorrhoeae requires a Src-like tyrosine kinase- and Rac1-dependent signalling pathway. EMBOJ 1998; 17: 443-454.
51. Kyriakis JM. Making the connection: Coupling of stress-activated ERK/MAPK (extracellular-signal-regulated kinase/mitogen-activated protein kinase) core signalling modules to extracellular stimuli and biological responses. Biochem Soc Symp 1999; 64: 29-48.
52. Deng X, Xiao L, Lang W, Gao F, Ruvolo P, May WS, Jr. Novel role for JNK as a stress-activated Bcl-2 kinase. J Biol Chem 2001; 276: 23681-23688.
53. Bennett BL, Sasaki DT, Murray BW, et al. SP600125: An anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001; 98: 13681-13686.
54. Gibson S, Widmann C, Johnson GL. Differential involvement of MEK kinase 1 (MEKK1) in the induction of apoptosis in response to microtubule-targeted drugs versus DNA damaging agents. J Biol Chem 1999; 274: 10916-10922.
55. Frisch SM, Vuori K, Kelaita D, Sicks S. A role for Jun-N-terminal kinase in anoikis; Suppression by Bcl-2 and crmA. J Biol Chem 1996; 135: 1377-1382.
56. Avruch J, Belham C, Weng Q, Hara K, Yonezawa K. Prog Mol Subcell Biol 2001; 26: 115-154.
57. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. Proc Natl Acad Sci USA 2001; 98: 9666-9670.
58. Harris LN, Yang L, Tang C, Yang D, Lupu R. Clin Cancer Res 1998; 4: 1005-1012.
59. Yamamoto K, Ichijo H, Korsmeyer, SJ. Bcl-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999; 19: 8469-8478.
60. Thornberry NA, Lazebnik Y. Caspases: Enemies within. Science 1998; 281: 1312-1316.
61. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998; 281: 1305-1308.
62. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-1312.
63. Nakagawa T, Zhu H, Morishima N, et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid. Nature 2000; 403: 98-103.
64. Lee JY, Hannun YA, Obeid LM. J Biol Chem 1996; 271: 13169-13174.
65. Whelan RDH, Parker PJ. Oncogene 1998; 16: 1939-1944.
66. Ruvolo PP, Deng X, Carr BK, May WS. J Biol Chem 1998; 273: 25436-25442.
67. Bourbon NA, Yun J, Kester M. Ceramide directly activates protein kinase C zeta to regulate a stress-activated protein kinase signaling complex. J Biol Chem 2000; 275: 35617-35623.